Aphios Pharma LLC - Science and Technology of Cannabis as a Medicine скачать в хорошем качестве

Aphios Pharma LLC - Science and Technology of Cannabis as a Medicine

About this Webinar: A discussion on the science and technology of medical cannabis and the drug-delivery nanotechnologies that make cannabis more medically effective. Aphios® Pharma LLC is a leading green biotech company developing sustained-release nano-encapsulated cannabinoids for highly unmet chronic medical needs. We've launched an equity crowdfunding campaign to help raise funds to enhance the efficacy of medical marijuana by using nanoencapsulation technology, which improves the stability of specific bioactive cannabinoids from oxygen degradation and keeps them in the body longer. This webinar will cover the science and technology of cannabis and cannabinoids as a medicine for several chronic diseases. On the science side, we will cover research and use of cannabis for anxiety and observational studies at the MIND Institute, Harvard Medical School. We will also cover research and use of cannabis for pain, opioid use disorder and multiple sclerosis. On the technology side, we will cover the manufacturing of pharmaceutical-grade cannabinoids from Cannabis sativa (marijuana) following current Good Manufacturing Practices (cGMP) of the US FDA. We will also cover the nanoencapsulation of these cannabinoids to improve their stability and sustain their release in the body to improve both safety and efficacy. Join Aphios Pharma Founder and CEO Dr. Trevor P. Castor, along with guest Dr. Judith L. Palmer-Castor and Dr. Staci A. Gruber for a discussion on the science of medical cannabis and the drug-delivery nanotechnologies that make cannabis more medically effective. About the Panelists Dr. Trevor P. Castor, Ph.D., President, and Chief Executive Officer, has over 30 years of diversified business experience ranging from management, marketing, and finance to technology and business development in the energy, environmental and biopharmaceutical industries. He has had bottom-line experience with several high-tech startups. Dr. Castor graduated from the University of California, Berkeley, with a Ph.D. in Mechanical Engineering and a Master of Science degree in Chemical Engineering. He graduated summa cum laude with a Bachelor of Science degree in Chemical Engineering from the University of Toronto, Toronto, Canada. He studied Business Administration at St. Mary’s College, Brooklyn, NY, and Management, Marketing, and Finance at the Harvard University Extension Program, Cambridge, MA. He is the primary author of 72 issued U.S. and international patents and 37 pending patents. Dr. Castor has collaborated with and consulted to several multinational companies including Baxter Healthcare, Bayer AG, Bristol-Myers Squibb, Eli Lilly, General Electric, Novartis AG and the Gillette Company, and financial institutions such as the Bank of New England and the New England Life Insurance Company. Dr. Judith Palmer-Castor, Director of Clinical and Regulatory Affairs, is a behavioral health scientist with over 20 years of research, clinical and regulatory experiences in industry and academia. Dr. Palmer-Castor was a Project Director on a HIV/AIDS Clinical Trial Network Project at Children’s Hospital, Harvard Medical School, Boston, MA, a consulting scientist for Mass General Hospital, Harvard Medical School - Division of Global Health and Human Rights, Boston, MA, as well as holding similar behavioral health and research and clinical positions at Northeastern University, Boston, MA, SAMSHA, CDC and other non-profit health and human service agencies. Dr. Palmer-Castor graduated with a Ph.D. in Policy with an emphasis on Behavioral Health and Adolescent Development from Brandeis University, Waltham, MA, and M.S. and B.S. degrees in Psychology from Santa Clara University, CA. Dr. Staci A. Gruber, Associate Professor of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA. Staci Gruber, PhD, is the director of the Cognitive and Clinical Neuroimaging Core and director of the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital. She is an associate professor of psychiatry at Harvard Medical School. Her research focuses on the application of neurocognitive models and neuroimaging to better characterize risk factors for substance misuse and psychiatric conditions. Dr. Gruber has been studying the impact of marijuana on the brain using neurocognitive, clinical and diagnostic assessments, and multimodal brain imaging techniques. She has worked to educate policymakers and the general public about the neurobiologic differences between adults and adolescents as well as additional factors that contribute to the impact of marijuana on the brain. In 2014, Dr. Gruber launched MIND, the first program of its kind designed to clarify the specific effects of medical marijuana use on a number of outcome measures.